This Has Won 99.1% Of Trades Over 3 Years
Video reveals the most powerful trade you’ve NEVER heard of. Released every Tuesday, it could DOUBLE your money by Friday.

In past 3 years, it’s won 321 out of 324 of these trades, with the majority making 100%+ every 3-10 days.

See how a simple 10-minute trade on Tue could double your money by Fri.

Watch Video Now For Full Details.
Martina Flammer, insider at Insmed

Martina Flammer Insider Information

Insider of Insmed
Martina joined Insmed in December 2019, bringing more than 17 years of industry experience in both medical and commercial roles. She has launched global brands and managed pipeline portfolios across therapeutic areas and geographies, including the U.S., Europe, Japan, and China. Martina was most recently Head of Corporate Division Customer Value, Senior Vice President at Boehringer Ingelheim International. Previous roles at Boehringer Ingelheim include Vice President Clinical Development & Medical Affairs, Specialty Care Business Unit, and Chief Medical Officer, Vice President of Medicine, Regulatory Affairs & Pharmacovigilance, Boehringer Ingelheim Canada. Prior to that, Martina held commercial and medical roles at Pfizer. She holds a medical degree from the University of Vienna Medical School, Austria, and completed post-doctoral training in internal and emergency medicine. She also holds a Master of Business Administration degree from New York University Stern School of Business.

What is Martina Flammer's salary?

As the Insider of Insmed Incorporated, Dr. Flammer earned a total compensation package of $3,934,370.00 in 2020. Dr. Flammer earned a salary of $500,000.00, a bonus of $150,000.00, stock awards of $249,993.00, options awards of $2,749,964.00, non-equity compensation of $267,600.00, and other compensation of $16,813.00. Learn More on Martina Flammer's salary.

How do I contact Martina Flammer?

The corporate mailing address for Dr. Flammer and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected] Learn More on Martina Flammer's contact information.

Has Martina Flammer been buying or selling shares of Insmed?

Martina Flammer has not been actively trading shares of Insmed over the course of the past ninety days. Learn More on Martina Flammer's trading history.

Who are Insmed's active insiders?

Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), and Michael Smith (VP). Learn More on Insmed's active insiders.

Are insiders buying or selling shares of Insmed?

In the last year, Insmed insiders bought shares 2 times. They purchased a total of 30,000 shares worth more than $645,500.00. In the last year, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 369,784 shares worth more than $9,936,562.97. The most recent insider tranaction occured on May, 11th when Director Melvin Md Sharoky bought 20,000 shares worth more than $344,000.00. Insiders at Insmed own 4.6 % of the company. Learn More about insider trades at Insmed.

Information on this page was last updated on 5/11/2022.

Martina Flammer Insider Trading History at Insmed

See Full Table

Martina Flammer Buying and Selling Activity at Insmed

This chart shows Martina M.D. Flammer's buying and selling at Insmed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Insmed Company Overview

Insmed logo
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More

Today's Range

Now: $20.89
Low: $19.58
High: $20.98

50 Day Range

MA: $19.78
Low: $17.07
High: $23.56

2 Week Range

Now: $20.89
Low: $16.41
High: $34.44


632,449 shs

Average Volume

937,410 shs

Market Capitalization

$2.50 billion

P/E Ratio


Dividend Yield



The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!